Inotiv (STU:BS50) Additional Paid-In Capital : €659.8 Mil(As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Inotiv Additional Paid-In Capital?

Inotiv's quarterly additional paid-in capital declined from Sep. 2023 (€670.6 Mil) to Dec. 2023 (€655.9 Mil) but then increased from Dec. 2023 (€655.9 Mil) to Mar. 2024 (€659.8 Mil).

Inotiv's annual additional paid-in capital increased from Sep. 2021 (€95.4 Mil) to Sep. 2022 (€714.9 Mil) but then declined from Sep. 2022 (€714.9 Mil) to Sep. 2023 (€670.6 Mil).

Inotiv Additional Paid-In Capital Historical Data

The historical data trend for Inotiv's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inotiv Additional Paid-In Capital Chart

Inotiv Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Additional Paid-In Capital

Get a 7-Day Free Trial

22.87

22.73

95.37

714.87

670.61

Inotiv Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															664.63	658.65	670.61	655.91	659.77

Inotiv Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Inotiv Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Inotiv's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Inotiv (STU:BS50) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inotiv Inc (STU:BS50) » Definitions » Additional Paid-In Capital

Comparable Companies

STIM FONR BNR ACRS PRPH VNRX MDXH BDSX BIOQ PSNL TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT

Traded in Other Exchanges

NOTV:USA

Address

2701 Kent Avenue, West Lafayette, IN, USA, 47906

Website

https://www.inotivco.com

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.

Inotiv (STU:BS50) Headlines

No Headlines